Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2 Meeting Abstract
| Authors: | McGregor, B. A.; Balar, A. V.; Rosenberg, J. E.; Van Der Heijden, M. S.; Park, S. H.; Lee, J. L.; Kojima, T.; Harrison, M. R.; Heath, E. I.; Stein, M. N.; Loriot, Y.; Necchi, A.; Steinberg, J. L.; Liang, S. Y.; Trowbridge, J.; Petrylak, D. P.; Yu, E. Y. |
| Abstract Title: | Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2 |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602272 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4524 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4524 -- Source: Wos |
